Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo.

Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo.

Immune-based anti-tumor or anti-angiogenic therapies hold considerable promise for the treatment of cancer. The first approach seeks to activate tumor antigen-specific T lymphocytes while, the second, delays tumor growth by interfering with blood supply. Tumor Associated Antigens are often employed...

Full description

Bibliographic Details
Main Authors: Lorena Aguilar-Guzmán, Lorena Lobos-González, Carlos Rosas, Gerardo Vallejos, Cristián Falcón, Eduardo Sosoniuk, Francisca Coddou, Lisette Leyton, David Lemus, Andrew F G Quest, Arturo Ferreira
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3995754?pdf=render

Internet

http://europepmc.org/articles/PMC3995754?pdf=render

Similar Items